Synergistic Immunochemotherapy Targeted SAMD4B-APOA2-PD-L1 Axis Potentiates Antitumor Immunity in Hepatocellular Carcinoma

Scientists proposed for the first time a synergistic immunochemotherapy that exerted a potent antitumor effect for patients with advanced hepatocellular carcinoma (HCC) in clinical practice based on three common antitumour drugs and found that HCC patients with new synergistic immunochemotherapy had better three-year overall survival than the control group.